BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 17080178)

  • 1. Ovarian cancer: a focus on management of recurrent disease.
    Herzog TJ; Pothuri B
    Nat Clin Pract Oncol; 2006 Nov; 3(11):604-11. PubMed ID: 17080178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in the management of epithelial ovarian cancer.
    Berkenblit A; Cannistra SA
    J Reprod Med; 2005 Jun; 50(6):426-38. PubMed ID: 16050567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapy for recurrent ovarian cancer.
    Kuhn WC
    Curr Womens Health Rep; 2003 Feb; 3(1):33-8. PubMed ID: 12521548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic therapy in recurrent ovarian cancer: current treatment options and new drugs.
    Harter P; Hilpert F; Mahner S; Heitz F; Pfisterer J; du Bois A
    Expert Rev Anticancer Ther; 2010 Jan; 10(1):81-8. PubMed ID: 20014888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of ovarian stromal cell tumors.
    Colombo N; Parma G; Zanagnolo V; Insinga A
    J Clin Oncol; 2007 Jul; 25(20):2944-51. PubMed ID: 17617526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secondary therapy for epithelial ovarian cancer--1994.
    Sutton GP
    Semin Oncol; 1994 Aug; 21(4 Suppl 7):32-6. PubMed ID: 8091239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of epithelial ovarian cancer].
    Langmár Z; Csömör S
    Orv Hetil; 2006 Aug; 147(34):1627-32. PubMed ID: 17017677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment of ovarian cancer].
    Cianti C
    Clin Ter; 2002; 153(2):135-44. PubMed ID: 12078339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of recurrent epithelial ovarian carcinoma.
    Vasey PA
    Aust N Z J Obstet Gynaecol; 2005 Aug; 45(4):269-77. PubMed ID: 16029291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ovarian cancer: strategies for overcoming resistance to chemotherapy.
    Agarwal R; Kaye SB
    Nat Rev Cancer; 2003 Jul; 3(7):502-16. PubMed ID: 12835670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extreme drug resistance assay results do not influence survival in women with epithelial ovarian cancer.
    Karam AK; Chiang JW; Fung E; Nossov V; Karlan BY
    Gynecol Oncol; 2009 Aug; 114(2):246-52. PubMed ID: 19500821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging role of pemetrexed in ovarian cancer.
    Tomao F; Panici PB; Frati L; Tomao S
    Expert Rev Anticancer Ther; 2009 Dec; 9(12):1727-35. PubMed ID: 19954283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy for gynecologic cancers.
    Rahaman J; Steiner N; Hayes MP; Chuang L; Fishman D; Gretz Iii H
    Mt Sinai J Med; 2009 Dec; 76(6):577-88. PubMed ID: 20014427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stage IVB endometrial cancer: does applying an ovarian cancer treatment paradigm result in similar outcomes? A case-control analysis.
    Landrum LM; Moore KN; Myers TK; Lanneau GS; McMeekin DS; Walker JL; Gold MA
    Gynecol Oncol; 2009 Feb; 112(2):337-41. PubMed ID: 19041126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advanced ovarian cancer: a clinical update on first-line treatment, recurrent disease, and new agents.
    Ozols RF
    J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S60-73. PubMed ID: 19780247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Second line platinum-based intraperitoneal chemotherapy for advanced ovarian cancer.
    Milczek T; Klasa-Mazurkiewicz D; Emerich J; Kobierski J
    Acta Obstet Gynecol Scand; 2009; 88(4):463-7. PubMed ID: 19235559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Whole-body hyperthermia (WBH) in combination with carboplatin in patients with recurrent ovarian cancer - a phase II study.
    Atmaca A; Al-Batran SE; Neumann A; Kolassa Y; Jäger D; Knuth A; Jäger E
    Gynecol Oncol; 2009 Feb; 112(2):384-8. PubMed ID: 19059635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive approach to advanced primary and recurrent ovarian cancer: a personal experience.
    Carmignani CP; Sugarbaker PH
    Expert Rev Anticancer Ther; 2004 Jun; 4(3):477-87. PubMed ID: 15161446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The changing landscape of therapeutic strategies for recurrent ovarian cancer.
    Baumann KH; Wagner U; du Bois A
    Future Oncol; 2012 Sep; 8(9):1135-47. PubMed ID: 23030488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complete remission of platinium refractory ovarian cancer with second line tegafur with uracil monotherapy: a case report.
    Camci C; Sevinc A; Aslan Y; Kalender ME; Buyukberber S
    Cancer Chemother Pharmacol; 2009 Mar; 63(4):745-8. PubMed ID: 18504578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.